Business in Asia / China / Denmark / Healthcare

Novo Nordisk boosts drug production in China

- by Charlotte Nike Albrechtsen - 2 Comments.

The Danish pharmaceutical company Novo Nordisk boosts its production in China by investing around US$ 556 million in its Chinese flagship factory in Tianjin. The sterile preparation expansion project has already been put in motion and is expected to be done in 2027.

This year marks the 30th anniversary of Novo Nordisk in China and could also be the year the renowned weight-loss drug Wegovy will be approved in China, where obesity and diabetes among the population is increasing.

The Chinese factory in Tianjin was opened 30 years ago in 1994.

Source: fiercepharma.com

Related posts:

Singapore approves Danish weight-loss drug Novo Nordisk experience big profit rise due to obesity treatments Novo Nordisk’s diet drug may land in China soon Wegovy approved in China

About Charlotte Nike Albrechtsen

Charlotte Nike Albrechtsen is a journalist working with ScandAsia at the headquarters in Bangkok.

View all posts by Charlotte Nike Albrechtsen →
0 0 votes
Article Rating
Subscribe
Notify of
guest

2 Comments
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
trackback
Novo Nordisk is expanding its footprint in China with a recruitment shakeup – Woodlacantinegourmande
1 year ago

[…] on China highlights the growing importance of the Asian market in Novo’s global strategy. Earlier this year, Novo announced a substantial investment of approximately US$556 million to expand its flagship factory in Tianjin, which it expects to […]

0
trackback
Novo Nordisk expands footprint in China with recruitment shift - Scandasia
1 year ago

[…] China highlights the increasing significance of the Asian market in Novo’s global strategy. Earlier this year, Novo announced a substantial investment of around US$ 556 million to expand its flagship factory in Tianjin, which it expects to complete […]

0